Trial Outcomes & Findings for Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy (NCT NCT02858908)

NCT ID: NCT02858908

Last Updated: 2025-09-11

Results Overview

Incidence of Adverse events (AEs), including serious adverse events (SAEs), between baseline to end of study.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

16 participants

Primary outcome timeframe

12 weeks

Results posted on

2025-09-11

Participant Flow

Subjects were to be male or female aged 12 to 45 years with a diagnosis of genetically confirmed congenital or juvenile-onset type 1 myotonic dystrophy. Subjects were to have a Clinical Global Impression- Severity (CGI-S) score of 4 or greater at Screening and Run-in (V2) and were to be ambulatory and able to complete the 10-metre walk/run test.

Participant milestones

Participant milestones
Measure
Cohort 1
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Overall Study
STARTED
8
8
Overall Study
COMPLETED
8
8
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Cohort 1
n=8 Participants
1000 mg tideglusib
Cohort 2
n=8 Participants
400 mg tideglusib
Total
n=16 Participants
Total of all reporting groups
Age, Customized
Mean
21.8 years
STANDARD_DEVIATION 5.5 • n=99 Participants
20.3 years
STANDARD_DEVIATION 6.36 • n=107 Participants
21 years
STANDARD_DEVIATION 5.8 • n=206 Participants
Sex: Female, Male
Female
5 Participants
n=99 Participants
1 Participants
n=107 Participants
6 Participants
n=206 Participants
Sex: Female, Male
Male
3 Participants
n=99 Participants
7 Participants
n=107 Participants
10 Participants
n=206 Participants
Race/Ethnicity, Customized
Not Hispanic or latino
8 Participants
n=99 Participants
8 Participants
n=107 Participants
16 Participants
n=206 Participants
Race/Ethnicity, Customized
White
8 Participants
n=99 Participants
7 Participants
n=107 Participants
15 Participants
n=206 Participants
Race/Ethnicity, Customized
Asian
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants

PRIMARY outcome

Timeframe: 12 weeks

Population: Safety Analysis Set

Incidence of Adverse events (AEs), including serious adverse events (SAEs), between baseline to end of study.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Safety (Adverse Events)
Total number of TEAEs
8 Participants
6 Participants
Safety (Adverse Events)
Total number of serious TEAEs
0 Participants
0 Participants
Safety (Adverse Events)
Total number of TEAEs leading to discontinuation of active treatment
0 Participants
0 Participants
Safety (Adverse Events)
Total number of TEAEs leading to withdrawal
0 Participants
0 Participants
Safety (Adverse Events)
Total number of TEAEs leading to death
0 Participants
0 Participants
Safety (Adverse Events)
Severity: Mild
3 Participants
1 Participants
Safety (Adverse Events)
Severity: Moderate
5 Participants
4 Participants
Safety (Adverse Events)
Severity: Severe
0 Participants
1 Participants
Safety (Adverse Events)
Unrelated to active treatment
6 Participants
6 Participants
Safety (Adverse Events)
Related to active treatment
2 Participants
0 Participants

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

Pharmacokinetic samples were collected to determine Tideglusib plasma concentration

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Plasma Concentration of Tideglusib
Maximum plasma concentration (Cmax)
1041.25 ng/mL
Standard Deviation 361.44
496.94 ng/mL
Standard Deviation 104.88
Plasma Concentration of Tideglusib
Minimum plasma concentration (Cmin)
8.63 ng/mL
Standard Deviation 5.68
5.14 ng/mL
Standard Deviation 4.06
Plasma Concentration of Tideglusib
Steady-state concentration (CSS)
133.7 ng/mL
Standard Deviation 60.79
54.27 ng/mL
Standard Deviation 16.54

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

Pharmacokinetic samples were collected to determine time of the maximum plasma concentration and terminal elimination half-life of tideglusib

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Blood Pharmacokinetics of Tideglusib
Time of the maximum plasma concentration (Tmax)
0.79 h
Standard Deviation 0.27
0.65 h
Standard Deviation 0.29
Blood Pharmacokinetics of Tideglusib
Terminal elimination half-life (T1/2)
1.82 h
Standard Deviation 0.64
2.68 h
Standard Deviation 1.70

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

Pharmacokinetic samples were collected to determine area under the plasma concentration vs. time curve from 0 to 12 h and area under the plasma concentration vs. time curve from 0 to 24 h of tideglusib

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Area Under the Plasma Concentration vs. Time Curve of Tideglusib
Area under the plasma concentration vs. time curve from 0 to 12 h (AUC0-12)
3054.27 ng/mL.h
Standard Deviation 1418.30
1214.88 ng/mL.h
Standard Deviation 390.81
Area Under the Plasma Concentration vs. Time Curve of Tideglusib
Area under the plasma concentration vs. time curve from 0 to 24 h (AUC0-24)
3208.8 ng/mL.h
Standard Deviation 1459.03
1302.42 ng/mL.h
Standard Deviation 396.96

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

The 10-metre walk/run test is a performance measure used to assess walking speed in metres per second over a short distance and was used as an assessment of functional mobility. Time taken to complete the 10m walk/run test at fastest and preferred speed is measured.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
10 Metre Walk/Run Test
Preferred speed (observed value at week 12)
9.1041 seconds
Standard Deviation 1.34351
9.1475 seconds
Standard Deviation 1.72651
10 Metre Walk/Run Test
Preferred speed (change from baseline at week 12)
-0.6616 seconds
Standard Deviation 1.96370
-0.6529 seconds
Standard Deviation 0.86109
10 Metre Walk/Run Test
Fastest speed (observed value at week 12)
4.2515 seconds
Standard Deviation 2.41439
4.4833 seconds
Standard Deviation 2.72809
10 Metre Walk/Run Test
Fastest speed (change from baseline at week 12)
-0.3894 seconds
Standard Deviation 0.32806
-0.0650 seconds
Standard Deviation 0.46428

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

Handgrip myometry is used as a measure of myotonia and muscle strength for the dominant hand

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Computerised Handgrip Myometer Measure of Grip Strength and Muscle Relaxation Time
Observed value (at week 12)
14.0899 kg
Standard Deviation 7.71583
14.1334 kg
Standard Deviation 6.86499
Computerised Handgrip Myometer Measure of Grip Strength and Muscle Relaxation Time
Change from baseline (at week 12)
1.0098 kg
Standard Deviation 3.09422
-1.4893 kg
Standard Deviation 2.89328

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

FVC is a measure of lung function (the total amount of air exhaled during a Forced Expiratory Volume is measured using a spirometer)

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Respiratory Forced Vital Capacity (FVC)
Observed value (at week 12)
2.1509 litres
Standard Deviation 0.93362
2.4220 litres
Standard Deviation 1.15969
Respiratory Forced Vital Capacity (FVC)
Change from baseline (at week 12)
-0.0179 litres
Standard Deviation 0.32603
0.0118 litres
Standard Deviation 0.36746

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

DXA utilises two low energy X-ray beams, with different energy levels, which are aimed at the subject's bones. The DXA scan is more typically used to measure bone mineral density, however it can also be used to measure total lean muscle mass

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Dual-energy X-ray Absorptiometry (DXA)
Arms (observed value at week 12)
3102.9 gram
Standard Deviation 898.69
4098.5 gram
Standard Deviation 1313.53
Dual-energy X-ray Absorptiometry (DXA)
Arms (change from baseline at week 12)
-252.8 gram
Standard Deviation 1038.49
35.9 gram
Standard Deviation 357.09
Dual-energy X-ray Absorptiometry (DXA)
Legs (observed value at week 12)
11767.0 gram
Standard Deviation 2980.78
12262.8 gram
Standard Deviation 3225.63
Dual-energy X-ray Absorptiometry (DXA)
Legs (change from baseline at week 12)
-62.5 gram
Standard Deviation 646.22
95.0 gram
Standard Deviation 299.82
Dual-energy X-ray Absorptiometry (DXA)
Total (observed value at week 12)
38267.6 gram
Standard Deviation 8274.58
37740.4 gram
Standard Deviation 8481.27
Dual-energy X-ray Absorptiometry (DXA)
Total (change from baseline at week 12)
411.6 gram
Standard Deviation 2040.84
391.9 gram
Standard Deviation 763.01

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

The CGI-S is a 7-point Likert type scale that requires the clinician to rate the severity of the subject's illness at the time of assessment, relative to the clinician's past experience with subjects who have the same diagnosis. Considering total clinical experience, a subject is assessed on severity of illness at the time of rating 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. Change in CGI-S was observed in only 1 subject. Consequently statistical analysis was not conducted.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Clinical Global Impressions- Severity (CGI-S)
Observed value at week 12
4.8 Values on a scale
Standard Deviation 1.16
4.9 Values on a scale
Standard Deviation 0.83
Clinical Global Impressions- Severity (CGI-S)
Change from baseline at week 12
-0.1 Values on a scale
Standard Deviation 0.35
0.0 Values on a scale
Standard Deviation 0.00

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

The CGI-I requires the clinician to rate how much the subject's illness has improved or worsened relative to a baseline state. A seven point Likert type scale is used from 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Clinical Global Impressions- Improvement (CGI-I)
3.1 Scores on a scale
Standard Deviation 0.83
3.0 Scores on a scale
Standard Deviation 1.07

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

Actigraphy is a non-invasive method of monitoring physical activity via an actigraph device. The actigraph device was worn on the waist during waking hours, according to the device's instruction manual.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Actigraphy (3-minute Bouts of Activity)
Weekly total number of 3 minute bouts of activity (observed value at week 12)
1.465 3 minute bouts of activity per hour
Standard Deviation 0.1780
0.938 3 minute bouts of activity per hour
Standard Deviation 0.5268
Actigraphy (3-minute Bouts of Activity)
Weekly total number of 3 minute bouts of activity (change from baseline at week 12)
-0.200 3 minute bouts of activity per hour
Standard Deviation 0.3959
-0.284 3 minute bouts of activity per hour
Standard Deviation 0.1805

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

Actigraphy is a non-invasive method of monitoring physical activity via an actigraph device. The actigraph device was worn on the waist during waking hours, according to the device's instruction manual.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Actigraphy (>10-minute Bouts of Activity)
Weekly total number of >10 minute bouts of activity (observed value at week 12)
0.048 10 minute bouts of activity per hour
Standard Deviation 0.0621
0.020 10 minute bouts of activity per hour
Standard Deviation 0.0245
Actigraphy (>10-minute Bouts of Activity)
Weekly total number of >10 minute bouts of activity (change from baseline at week 12)
-0.010 10 minute bouts of activity per hour
Standard Deviation 0.0600
0.006 10 minute bouts of activity per hour
Standard Deviation 0.0313

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

Actigraphy is a non-invasive method of monitoring physical activity via an actigraph device. The actigraph device was worn on the waist during waking hours, according to the device's instruction manual.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Actigraphy (Steps)
Weekly total number of steps (observed value at week 12)
556.387 steps per hour wear time
Standard Deviation 255.6433
352.518 steps per hour wear time
Standard Deviation 263.1992
Actigraphy (Steps)
Weekly total number of steps (change from baseline at week 12)
-51.427 steps per hour wear time
Standard Deviation 198.9754
-53.802 steps per hour wear time
Standard Deviation 89.0843

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

Measure of fine manual dexterity. Time to taken to complete the NHPT (dominant hand) is recorded.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Nine Hole Peg Test (NHPT)
Observed value at week 12
23.590 seconds
Standard Deviation 8.2592
24.760 seconds
Standard Deviation 3.8275
Nine Hole Peg Test (NHPT)
Change from baseline at week 12
-2.168 seconds
Standard Deviation 3.9007
-0.950 seconds
Standard Deviation 1.7080

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

The Top 3 concerns VAS allows caregivers to identify their main three causes of concern, related to the subject's myotonic dystrophy, rather than these being pre-specified within a scale and then rating how these concerns have changed at specific time-points during the study. Subjects, where possible, and caregivers were asked to rate three causes for concern by drawing a vertical mark on a 10 cm long visual analogue scale with anchors of "not at all severe" at the left end (0 cm) and "very severe" at the right end (10 cm). A score for each concern was to be determined by measuring the number of centimeters on the 10 cm VAS line from the anchor point on the left side of the line. A total VAS score for each subject was calculated as the sum of the scores for the 3 concerns (minimum = 0 cm, maximum = 30 cm). A higher score represents a worse outcome.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Top 3 Concerns Visual Analogue Scale (VAS) Score
Subject Top 3 Concerns VAS total score (observed value at week 12)
15.66 Score on a scale
Standard Deviation 6.331
15.29 Score on a scale
Standard Deviation 5.641
Top 3 Concerns Visual Analogue Scale (VAS) Score
Subject Top 3 Concerns VAS total score (change from baseline at week 12)
-1.76 Score on a scale
Standard Deviation 3.455
-2.00 Score on a scale
Standard Deviation 2.598
Top 3 Concerns Visual Analogue Scale (VAS) Score
Caregiver Top 3 Concerns VAS total score (observed value at week 12)
18.84 Score on a scale
Standard Deviation 3.583
16.58 Score on a scale
Standard Deviation 6.151
Top 3 Concerns Visual Analogue Scale (VAS) Score
Caregiver Top 3 Concerns VAS total score (change from baseline at week 12)
-2.39 Score on a scale
Standard Deviation 2.669
-1.98 Score on a scale
Standard Deviation 2.001

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

The OARS-4 contains the autism signs and symptoms in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. These were to be rated with the degree of impairment the subject experiences for the given symptom. The symptoms were to be elicited in a semi-structured interview with the subject's primary caregiver. The assessor was to take both frequency/duration and degree of impairment into account and how much the item interferes with relationships, learning, and/or activities of daily living. The scores for this assessment were from 0 (Never or Rarely; Not a Problem) to 3 (Very Often; A Severe Problem): a score for each symptom of social impairment, communication impairment and restricted patterns were averaged to provide a total impairment score. A higher score represents a worse outcome (minimum = 0, maximum 3).

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Ohio State University (OSU) Autism Rating Scale (OARS)
Total impairment mean (observed value at week 12)
0.239 Units on a scale
Standard Deviation 0.3178
0.303 Units on a scale
Standard Deviation 0.4946
Ohio State University (OSU) Autism Rating Scale (OARS)
Total impairment mean (change from baseline at week 12)
-0.054 Units on a scale
Standard Deviation 0.0782
-0.010 Units on a scale
Standard Deviation 0.0283

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

The OSU Autism CGI scale contains separate subscales for symptom severity and for global improvement. These are rated in a similar way to the National Institute of Mental Health (NIMH) CGI Severity scale, but it is focused on autism spectrum symptoms. OSU Autism CGI-severity and OSU Autism CGI-improvement scores use a seven point Likert rating scale from 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Ohio State University (OSU) Autism Clinical Global Impression (CGI)
OSU autism CGI-Severity (observed value at week 12)
1.9 Units on a scale
Standard Deviation 0.99
2.3 Units on a scale
Standard Deviation 1.83
Ohio State University (OSU) Autism Clinical Global Impression (CGI)
OSU autism CGI-Severity (change from baseline at week 12)
-0.1 Units on a scale
Standard Deviation 0.35
0 Units on a scale
Standard Deviation 0
Ohio State University (OSU) Autism Clinical Global Impression (CGI)
OSU autism CGI-Improvement (observed value at week 12)
3.4 Units on a scale
Standard Deviation 0.74
4 Units on a scale
Standard Deviation 0

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

The Clinician-completed Domain Specific Causes for Concern is a Visual Analogue Scale completed by the clinician that scores the severity of concerns of domains that are clinically relevant in myotonic dystrophy. The severity of the clinician's concern is scored by using a 10 cm visual analogue scale (VAS), with anchors of "not at all severe" at the left end (0 cm) and "very severe" at the right end (10 cm). The clinician is asked to make a vertical line indicating his/her level of concern in each domain, using a time frame of the past week for reference. A score is to be determined by measuring the number of centimeters on the 10 cm VAS line from the anchor point on the left side of the line. A total VAS score for each subject was calculated as the sum of the scores for the 17 domains (minimum = 0, maximum = 170 cm). A higher score represents a worse outcome.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Clinician-completed Domain Specific Cause for Concern Visual Analogue Scale (VAS): Myotonic Dystrophy
VAS total score (observed value at week 12)
51.19 Score on a scale
Standard Deviation 8.798
59.28 Score on a scale
Standard Deviation 17.450
Clinician-completed Domain Specific Cause for Concern Visual Analogue Scale (VAS): Myotonic Dystrophy
VAS total score (change from baseline at week 12)
-5.80 Score on a scale
Standard Deviation 4.855
-3.38 Score on a scale
Standard Deviation 2.726

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

The PPVT-4 scale is a norm-referenced instrument for measuring the receptive (hearing) vocabulary of children and adults. It contains training items and 228 test items, each consisting of four full-colour pictures as response options on a page. For each item, the examiner says a word, and the examinee responds by selecting the picture that best illustrates that word's meaning. Each administration of the test produces a raw score (number of test items answered correctly), which can be converted to a standard score (using age-based norms) with a mean of 100 and a standard deviation of 15. Higher scores mean a better performance/receptive vocabulary.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Peabody Picture Vocabulary Test (PPVT)
Age-based standard score (observed value at week 12)
63.8 Units on a scale
Standard Deviation 15.81
79.8 Units on a scale
Standard Deviation 22.23
Peabody Picture Vocabulary Test (PPVT)
Age-based standard score (change from baseline at week 12)
-0.1 Units on a scale
Standard Deviation 7.97
-1.1 Units on a scale
Standard Deviation 5.57

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set

Total levels of GSK3β protein was determined via x-MAP technology in a Luminex 200 platform using the AKT Pathway Total Multispecies 7-Plex Panel from ThermoFisher Scientific.

Outcome measures

Outcome measures
Measure
Cohort 1
n=8 Participants
Subjects were given tideglusib 1000 mg for 12 weeks (weeks 0 to 12)
Cohort 2
n=8 Participants
Subjects were given tideglusib 400 mg for 12 weeks (weeks 0 to 12)
Biomarker - Lymphocyte GSK3β Levels and Activity
1.42 microgram per microliter
Standard Deviation 0.81
1.95 microgram per microliter
Standard Deviation 0.79

Adverse Events

Cohort 1

Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths

Cohort 2

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Cohort 1
n=8 participants at risk
1000 mg tideglusib
Cohort 2
n=8 participants at risk
400 mg tideglusib
Injury, poisoning and procedural complications
Back injury
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Injury, poisoning and procedural complications
Fall
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Injury, poisoning and procedural complications
Joint dislocation
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Injury, poisoning and procedural complications
Laceration
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Injury, poisoning and procedural complications
Limb injury
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
12.5%
1/8 • Number of events 2 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Respiratory, thoracic and mediastinal disorders
Cough
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Nervous system disorders
Headache
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Nervous system disorders
Nervous system cyst
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Nervous system disorders
Somnolence
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Gastrointestinal disorders
Vomiting
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
25.0%
2/8 • Number of events 2 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Gastrointestinal disorders
Diarrhea
25.0%
2/8 • Number of events 2 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Gastrointestinal disorders
Abdominal pain
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Gastrointestinal disorders
Post-tussive vomiting
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Reproductive system and breast disorders
Dysmenorrhea
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Skin and subcutaneous tissue disorders
Eczema
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Skin and subcutaneous tissue disorders
Erythema
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Skin and subcutaneous tissue disorders
Rash papular
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Musculoskeletal and connective tissue disorders
Arthralgia
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Musculoskeletal and connective tissue disorders
Axillary mass
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Musculoskeletal and connective tissue disorders
Myalgia
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Metabolism and nutrition disorders
Vitamin D deficiency
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Infections and infestations
Nasopharyngitis
25.0%
2/8 • Number of events 2 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
37.5%
3/8 • Number of events 4 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Infections and infestations
Lower respiratory tract infection
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Infections and infestations
Subcutaneous abscess
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
Infections and infestations
Urinary tract infection
0.00%
0/8 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.
12.5%
1/8 • Number of events 1 • Consent to end of study, up to 14 weeks
SAEs were collected from the time of informed consent. Non-serious AEs were collected from the time of single-blind dosing. Any non-serious medical occurrences occurring between Screening (visit 1) and Run in (visit 2) were recorded as Medical/Surgical History. Any non-serious signs and symptoms occurring between Screening (visit 1) and Run in (visit 2) were recorded and classified as baseline signs and symptoms.

Additional Information

Dr. Mike Snape, Chief Scientific Officer

AMO Pharma Ltd.

Phone: +44 (0) 7775915639

Results disclosure agreements

  • Principal investigator is a sponsor employee The investigator has the right to publish study results from his/her specific site. However, any publication that includes AMO Pharma confidential information cannot be submitted for publication without AMO Pharma's prior written approval.
  • Publication restrictions are in place

Restriction type: OTHER